Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2

Trial Profile

Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Esketamine (Primary)
  • Indications Tinnitus
  • Focus Registrational; Therapeutic Use
  • Acronyms TACTT2
  • Sponsors Auris Medical
  • Most Recent Events

    • 10 Nov 2016 According to Auris Medical media release, safety outcomes from this trial were presented at the 2016 Annual Meeting & OTO EXPOSM of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF)
    • 11 Oct 2016 Results published in the Auris Medical Media Release.
    • 18 Aug 2016 Top-line results from this study will be presented in a webcast, as per Auris Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top